Resverlogix’ RVX-208 is the First BET Bromodomain Inhibitor in Clinical Trials
CALGARY, Apr. 23, 2012 /CNW-AsiaNet/ – This Novel Epigenetic Mechanism Defines an Entirely New Class of Therapeutic TSX Exchange Symbol: RVX Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) today announces […]
Resverlogix Conference Call & Webcast to Announce Platform Mechanism of Action
CALGARY, Alberta, Canada, Apr. 19, 2012 /CNW-AsiaNet/ – Dr. Stephen J. Nicholls joins as guest speaker TSX Exchange Symbol: RVX Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) is pleased […]